Amy­lyx re­veals full da­ta that drove piv­otal fail­ure for ALS drug: #AAN24

Amy­lyx out­lined the scope of its Phase 3 de­feat, demon­strat­ing the ex­tent to which its now-with­drawn ALS drug Re­lyvrio failed to sep­a­rate it­self from place­bo …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.